Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Income from Continuing Operations (2016 - 2025)

Integra Lifesciences Holdings' Income from Continuing Operations history spans 17 years, with the latest figure at 1704000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 108.77% year-over-year to 1704000.0; the TTM value through Dec 2025 reached 516474000.0, down 7338.77%, while the annual FY2025 figure was 516474000.0, 7337.7% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 1704000.0 at Integra Lifesciences Holdings, up from 5404000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 52946000.0 in Q4 2022 and bottomed at 484073000.0 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 19665500.0 (2023), against an average of 5302550.0.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 9603.52% in 2021 before it plummeted 3803.18% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 45384000.0 in 2021, then rose by 16.66% to 52946000.0 in 2022, then crashed by 62.54% to 19834000.0 in 2023, then fell by 2.01% to 19435000.0 in 2024, then plummeted by 108.77% to 1704000.0 in 2025.
  • Per Business Quant, the three most recent readings for IART's Income from Continuing Operations are 1704000.0 (Q4 2025), 5404000.0 (Q3 2025), and 484073000.0 (Q2 2025).